Gastric cancer remains one of the most common cancers globally. The pathogenesis of intestinal-type gastric cancer involves pre-malignant stages, including gastric intestinal metaplasia (GIM), the replacement of native gastric foveolar and/or glandular epithelium by intestinal-type epithelium. GIM prevalence is highly variable based on geography and race/ethnicity partly due to the varying prevalence of H. pylori, a potent risk factor. However, gastric cancer incidence does not mirror that of H. pylori, demonstrating a complex interaction between H. pylori and risk factors. We will discuss the epidemiology of GIM and gastric cancer, including incidence trends, risk factors, and implications for future management.
SungHFerlayJSiegelRL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2.
ArnoldMFerlayJvan Berge HenegouwenMISoerjomataramI.Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564-1571. doi:10.1136/gutjnl-2020-321600
3.
CorreaP.Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211-217. doi:10.1016/j.gtc.2013.01.002
DixonMFGentaRMYardleyJHCorreaP.Classification and grading of gastritis. The updated Sydney System. International Workshop on the histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161-1181. doi:10.1097/00000478-199610000-00001
6.
AltayarODavitkovPShahSC, et al. AGA technical review on gastric intestinal metaplasia-epidemiology and risk factors. Gastroenterology. 2020;158(3):732-744.e16. doi:10.1053/j.gastro.2019.12.002
7.
MorganEArnoldMCamargoMC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalMedicine. 2022;47:101404. doi:10.1016/j.eclinm.2022.101404
8.
ArnoldMKarim-KosHECoeberghJW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2015;51(9):1164-1187. doi:10.1016/j.ejca.2013.09.002
9.
WongMCSHuangJChanPSF, et al. Global incidence and mortality of gastric cancer, 1980-2018. JAMA Netw Open. 2021;4(7):e2118457. doi:10.1001/jamanetworkopen.2021.18457
10.
HowsonCPHiyamaTWynderEL.The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1-27. doi:10.1093/oxfordjournals.epirev.a036288
11.
FockKMAngTL.Epidemiology ofHelicobacter pyloriinfection and gastric cancer in Asia. J Gastroenterol Hepatol. 2010;25(3):479-486. doi:10.1111/j.1440-1746.2009.06188.x
12.
AllemaniCMatsudaTDi CarloV, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3
13.
LagergrenFXieSHMattssonFLagergrenJ.Updated incidence trends in cardia and non-cardia gastric adenocarcinoma in Sweden. Acta Oncol. 2018;57(9):1173-1178. doi:10.1080/0284186X.2018.1457797
14.
AndersonWFRabkinCSTurnerNFraumeniJFJrRosenbergPSCamargoMC.The changing face of noncardia gastric cancer incidence among US Non-Hispanic Whites. J Natl Cancer Inst. 2018;110(6):608-615. doi:10.1093/jnci/djx262
15.
ColquhounAArnoldMFerlayJGoodmanKJFormanDSoerjomataramI.Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881-1888. doi:10.1136/gutjnl-2014-308915
16.
ThriftAPEl-SeragHB.Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534-542. doi:10.1016/j.cgh.2019.07.045
17.
SurveillanceE; End Results (SEER). Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 8 Registries, Nov 2021 Sub (1975-2019) - Linked To County Attributes - Time Dependent (1990-2019) Income/Rurality, 1969-2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April2022, based on the November 2021 submission.
18.
ParsonnetJFriedmanGDVandersteenDP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127-1131. doi:10.1056/NEJM199110173251603
19.
PlummerMFranceschiSVignatJFormanDde MartelC.Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136(2):487-490. doi:10.1002/ijc.28999
20.
EslickGDLimLLBylesJEXiaHHTalleyNJ.Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94(9):2373-2379. doi:10.1111/j.1572-0241.1999.01360.x
21.
HooiJKYLaiWYNgWK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429. doi:10.1053/j.gastro.2017.04.022
22.
NagyPJohanssonSMolloy-BlandM.Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut Pathog. 2016;8:8. doi:10.1186/s13099-016-0091-7
23.
World Gastroenterology Organisation. World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol. 2011;45(5):383-388. doi:10.1097/MCG.0b013e31820fb8f6
24.
LuoGZhangYGuoPWangLHuangYLiK.Global patterns and trends in stomach cancer incidence: age, period and birth cohort analysis. Int J Cancer. 2017;141(7):1333-1344. doi:10.1002/ijc.30835
25.
EverhartJEKruszon-MoranDPerez-PerezGITralkaTSMcQuillanG.Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis. 2000;181(4):1359-1363. doi:10.1086/315384
26.
OhkumaKOkadaMMurayamaH, et al. Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia. J Gastroenterol Hepatol. 2000;15(10):1105-1112. doi:10.1046/j.1440-1746.2000.02305.x
27.
FonthamETRuizBPerezAHunterFCorreaP.Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol. 1995;90(7):1094-1101.
28.
PlummerMvan DoornLJFranceschiS, et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst. 2007;99(17):1328-1334. doi:10.1093/jnci/djm120
29.
FormanDWebbPParsonnetJ.H pylori and gastric cancer. Lancet. 1994;343(8891):243-244.
30.
MoraisSCostaAAlbuquerqueG, et al. “True” Helicobacter pylori infection and non-cardia gastric cancer: a pooled analysis within the stomach cancer pooling (StoP) project. Helicobacter. 2022;27(3):e12883. doi:10.1111/hel.12883
31.
HuangJQZhengGFSumanacKIrvineEJHuntRH.Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003;125(6):1636-1644. doi:10.1053/j.gastro.2003.08.033
32.
ChoiCESonnenbergATurnerKGentaRM.High prevalence of gastric preneoplastic lesions in East Asians and Hispanics in the USA. Dig Dis Sci. 2015;60(7):2070-2076. doi:10.1007/s10620-015-3591-2
33.
NguyenTHTanMCLiuYRuggeMThriftAPEl-SeragHB.Prevalence of gastric intestinal metaplasia in a multiethnic US veterans population. Clin Gastroenterol Hepatol. Feb. 2021;19(2):269-276.e3. doi:10.1016/j.cgh.2020.03.015
34.
DongEDuanLWuBU.Racial and ethnic minorities at increased risk for gastric cancer in a regional US population study. Clin Gastroenterol Hepatol. 2017;15(4):511-517. doi:10.1016/j.cgh.2016.11.033
35.
JinHPinheiroPSXuJAmeiA.Cancer incidence among Asian American populations in the United States, 2009-2011. Int J Cancer. 2016;138(9):2136-2145. doi:10.1002/ijc.29958
36.
Ladeiras-LopesRPereiraAKNogueiraA, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control. 2008;19(7):689-701. doi:10.1007/s10552-008-9132-y
37.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438.
38.
SahaSK.Smoking habits and carcinoma of the stomach: a case-control study. Jpn J Cancer Res. 1991;82(5):497-502. doi:10.1111/j.1349-7006.1991.tb01878.x
39.
TaylerRPiperDW.The carcinogenic effect of cigarette smoke. The effect of cigarette smoke on human gastric mucosal cells in organ culture. Cancer. 1977;39(6):2520-2523. doi:10.1002/1097-0142(197706)39:6<2520::aid-cncr2820390632>3.0.co;2-c
40.
ThriftAPJoveAGLiuYTanMCEl-SeragHB.Associations of duration, intensity, and quantity of smoking with risk of gastric intestinal metaplasia. J Clin Gastroenterol. 2022;56(1):e71-e76. doi:10.1097/MCG.0000000000001479
41.
Pérez-StableEJHerreraBJacobP3rdBenowitzNL.Nicotine metabolism and intake in black and white smokers. JAMA. 1998;280(2):152-156. doi:10.1001/jama.280.2.152
42.
HoJYEloIT.The contribution of smoking to black-white differences in U.S. mortality. Demography. 2013;50(2):545-568. doi:10.1007/s13524-012-0159-z
43.
SellersEM.Pharmacogenetics and ethnoracial differences in smoking. JAMA. 1998;280(2):179-180. doi:10.1001/jama.280.2.179
44.
FerroAMoraisSRotaM, et al. Tobacco smoking and gastric cancer: meta-analyses of published data versus pooled analyses of individual participant data (StoP Project). Eur J Cancer Prev. 2018;27(3):197-204. doi:10.1097/CEJ.0000000000000401
45.
Alcohol drinking. IARC Working Group, Lyon, 13-20 October 1987. IARC Monogr Eval Carcinog Risks Hum. 1988;44:1-378.
46.
TanMCMallepallyNLiuYEl-SeragHBThriftAP.Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol. 2020;115(3):381-387. doi:10.14309/ajg.0000000000000498
47.
RussoAMaconiGSpinelliP, et al. Effect of lifestyle, smoking, and diet on development of intestinal metaplasia in H. pylori -positive subjects. Am J Gastroenterol. 2001;96(5):1402-1408. doi:10.1111/j.1572-0241.2001.03773.x
48.
HolmesHMJoveAGTanMCEl-SeragHBThriftAP.Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. veterans population. PLoS One. 2021;16(11):e0260019. doi:10.1371/journal.pone.0260019
49.
DengWJinLZhuoHVasiliouVZhangY.Alcohol consumption and risk of stomach cancer: a meta-analysis. Chem Biol Interact. 2021;336:109365. doi:10.1016/j.cbi.2021.109365
50.
RotaMPelucchiCBertuccioP, et al. Alcohol consumption and gastric cancer risk-A pooled analysis within the StoP project consortium. Int J Cancer. 2017;141(10):1950-1962. doi:10.1002/ijc.30891
51.
TanMCMallepallyNHoQLiuYEl-SeragHBThriftAP.Dietary factors and gastric intestinal metaplasia risk among US veterans. Dig Dis Sci. 2021;66(5):1600-1610. doi:10.1007/s10620-020-06399-9
52.
Dias-NetoMPintalhaoMFerreiraMLunetN.Salt intake and risk of gastric intestinal metaplasia: systematic review and meta-analysis. Nutr Cancer. 2010;62(2):133-147. doi:10.1080/01635580903305391
53.
MoraisSCostaAAlbuquerqueG, et al. Salt intake and gastric cancer: a pooled analysis within the stomach cancer pooling (StoP) project. Cancer Causes Control. 2022;33(5):779-791. doi:10.1007/s10552-022-01565-y
54.
World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report2018. Diet n, physical activity and stomach cancer. dietandcancerreport.org
55.
ZhaoZYinZZhaoQ.Red and processed meat consumption and gastric cancer risk: a systematic review and meta-analysis. Oncotarget. 2017;8(18):30563-30575. doi:10.18632/oncotarget.15699
56.
BaeJMKimEH.Dietary intakes of citrus fruit and risk of gastric cancer incidence: an adaptive meta-analysis of cohort studies. Epidemiol Health. 2016;38:e2016034. doi:10.4178/epih.e2016034
57.
KimKChangYAhnJ, et al. Body mass index and risk of intestinal metaplasia: a cohort study. Cancer Epidemiol Biomarkers Prev. 2019;28(4):789-797. doi:10.1158/1055-9965.EPI-18-0733
58.
LinXJWangCPLiuXD, et al. Body mass index and risk of gastric cancer: a meta-analysis. Jpn J Clin Oncol. 2014;44(9):783-791. doi:10.1093/jjco/hyu082
59.
TianTZhangLQMaXHZhouJNShenJ.Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes. 2012;120(4):217-223. doi:10.1055/s-0031-1297969
60.
GeZBenQQianJWangYLiY.Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2011;23(12):1127-1135. doi:10.1097/MEG.0b013e32834b8d73
61.
MiaoZFXuHXuYY, et al. Diabetes mellitus and the risk of gastric cancer: a meta-analysis of cohort studies. Oncotarget. 2017;8(27):44881-44892. doi:10.18632/oncotarget.16487
62.
DaboBPelucchiCRotaM, et al. The association between diabetes and gastric cancer: results from the Stomach Cancer Pooling Project Consortium. Eur J Cancer Prev. 2022;31(3):260-269. doi:10.1097/CEJ.0000000000000703
63.
FolletJCorcosLBaffetG, et al. The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis. Br J Cancer. 2012;106(4):685-692. doi:10.1038/bjc.2012.6
64.
SpenceADBusbyJHughesCMJohnstonBTColemanHGCardwellCR.Statin use and survival in patients with gastric cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf. 2019;28(4):460-470. doi:10.1002/pds.4688
65.
WinTTAyeSNLau Chui FernJOng FeiC.Aspirin and reducing risk of gastric cancer: systematic review and meta-analysis of the observational studies. J Gastrointest Liver Dis. 2020;29(2):191-198. doi:10.15403/jgld-818
66.
YangPZhouYChenB, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci. 2010;55(6):1533-1539. doi:10.1007/s10620-009-0915-0
67.
SheuBSTsaiYCWuCTChangWLChengHCYangHB.Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication. Helicobacter. 2013;18(2):117-123. doi:10.1111/hel.12013
68.
LeungWKNgEKChanFK, et al. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res. 2006;12(15):4766-4772. doi:10.1158/1078-0432.CCR-06-0693
69.
El-OmarEMOienKMurrayLS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology. 2000;118(1):22-30. doi:10.1016/s0016-5085(00)70410-0
70.
LeungWKNgEKChanWY, et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2982-2986. doi:10.1158/1055-9965.EPI-05-0181
71.
LiZWWuYSunY, et al. Inflammatory cytokine gene polymorphisms increase the risk of atrophic gastritis and intestinal metaplasia. World J Gastroenterol. 2010;16(14):1788-1794. doi:10.3748/wjg.v16.i14.1788
72.
ZhuFLohMHillJ, et al. Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study. BMC Gastroenterol. 2009;9:76. doi:10.1186/1471-230X-9-76
73.
YaghoobiMBijarchiRNarodSA.Family history and the risk of gastric cancer. Br J Cancer. 2010;102(2):237-242. doi:10.1038/sj.bjc.6605380
74.
DhillonPKFarrowDCVaughanTL, et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer. 2001;93(1):148-152. doi:10.1002/ijc.1294
75.
SetiaNClarkJWDudaDG, et al. Familial gastric cancers. Oncologist. 2015;20(12):1365-1377. doi:10.1634/theoncologist.2015-0205
76.
RawlaPBarsoukA.Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38. doi:10.5114/pg.2018.80001
77.
CasamayorMMorlockRMaedaHAjaniJ.Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018;12:883. doi:10.3332/ecancer.2018.883
78.
RokkasTPistiolasDSechopoulosPRobotisIMargantinisG.The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12 Suppl 2:2-38. doi:10.1111/j.1523-5378.2007.00563.x
79.
ChenHNWangZLiXZhouZG.Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166-175. doi:10.1007/s10120-015-0462-7
80.
GuptaSLiDEl SeragHB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158(3):693-702. doi:10.1053/j.gastro.2019.12.003
81.
FordACFormanDHuntRHYuanYMoayyediP.Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi:10.1136/bmj.g3174
82.
LeeYCChiangTHChouCK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113-1124.e5. doi:10.1053/j.gastro.2016.01.028
83.
ZengMMaoXHLiJX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(10002):1457-1464. doi:10.1016/S0140-6736(15)60310-5
84.
SuttonPBoagJM.Status of vaccine research and development for Helicobacter pylori. Vaccine. 2019;37(50):7295-7299. doi:10.1016/j.vaccine.2018.01.001
85.
AreiaMCarvalhoRCadimeATRocha GonçalvesFDinis-RibeiroM.Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013;18(5):325-337. doi:10.1111/hel.12050
86.
ZhangXLiMChenS, et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology. Aug. 2018;155(2):347-354.e9. doi:10.1053/j.gastro.2018.04.026
